Navigation Links
fits in Medical Technology

Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)

...a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of the hand), light weight, and battery use, products incorporating eFlow Technology reduce the burden of taking daily, inhaled treatments...

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans

...a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, products incorporating eFlow Technology reduce the burden of taking daily, inhaled treatment...

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

...a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, products incorporating eFlow Technology reduce the burden of taking daily, inhaled treatment...

Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient

... HOUSTON, May 18 /PRNewswire-USNewswire/ -- When treating the diabetes patient, doctors discussed how a "one size fits all" approach to testing is not enough to reveal an individual's risk for cardiovascular disease Saturday at the American Association of Clinical Endo...

Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy

... $12 billion per year. ToleroMune technology has additional potential regulatory and supply benefits for Circassia. Its state-of-the-art manufacturing fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, ...

Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients

... the condition. ToleroMune technology has additional potential regulatory and supply benefits for Circassia. Its state-of-the-art manufacturing fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, ...

Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis

...d lead author of the study. "However, it is also exciting to have interim results that indicate the use of Clobex Spray followed by Vectical Ointment fits well within accepted and common psoriasis treatment regimens." "These study results reinforce our commitment to bringing safe and effective thera...

Beating Blood Clots after Joint Replacement

...spital, in Charleston, SC. "The type of prophylaxis a patient may receive is often tailored on an individual basis, so there is not always a 'one-size fits all method' of prophylaxis available." More than 700,000 primary total hip and knee replacements are performed each year in the Uni...

Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease

...R Cysteamine in patients with Huntington's Disease. Our formation work with DR Cysteamine in conjunction with the CHU d'Angers studies in Huntington's fits our strategic plan to explore multiple potential indications for cysteamine and DR Cysteamine. Cysteamine has demonstrated neuroprotective effects in ...

VAI Finding Could Lead to New Drugs for Anxiety, Depression

... binds to CRF and other proteins in the same family. This detailed structural information can help drug developers engineer a drug that more perfectly fits to the receptor, making the drug more potent. Researchers determined the structure of the receptor in three different scenarios -- one with nothing bo...

In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices

...Spencer, Director of Support Services at The Center for Hospice and Palliative Care in South Bend, IN. "We feel what we are doing as a Hospice program fits into our philosophy for life and we are able to do that because of our success locally and participation at the national level. We believe it is time ...

APTA Supports Surgeon General's 'Call to Action' to Prevent Deep Vein Thrombosis and Pulmonary Embolism

... of stress on the lower back, especially for people who have pre-existing back problems. If you have brought along hand luggage or a rolling case that fits under the seat, use them as foot rests to elevate your feet so that your knees are slightly higher than your hips when you are sitting," suggests Moff...

Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular Excitation

..., where such experimental capabilities would be desirable. The PSD system controller is a fully contained, easy to use electronics base that readily fits into any bench-top environment. Cells for experimentation are grown on the silicon PSD substrates that fit in industry standard 24 well plates for cel...

Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent

...he first quickly accessible product to treat HAE patients offered in a convenient pre-filled syringe for subcutaneous administration. FIRAZYR not only fits our HGT portfolio but also leverages our capabilities of building successful global products for rare diseases." Prof. Dr. Jens Schneider-Mergener, ...

Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy

...n in the United States and in the European Union. Sylvie Gregoire, President of Shire's Human Genetic Therapies business, commented: "This product fits very well with Shire's ERT portfolio of treatments for Lysosomal Storage Disorders (LSD). Shire HGT has been committed to MLD and by acquiring this mi...

PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study

...a high proportion of respirable droplets delivered in the shortest possible amount of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, eFlow helps reduce the burden of taking daily inhaled treatments. About PARI Pharma PARI...

Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial

...oundation to sign up for participation in the Registry program. If they consent, then they are notified by the Foundation if a current or future trial fits their specific disease indications. Matthew Alsante, Executive Director, Sarcoma Foundation of America, states, "The collaboration allows for a superi...

PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation

...a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, eFlow helps reduce the burden of taking daily, inhaled treatments. Aztreonam lysine for in...

MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera

... is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already completed two Phase 3 clinical trials and that fits our strategic focus and complements our lead product candidate, EcoNail(R) for treatment of nail fungus," stated Robert J. DeLuccia, President and CEO...

Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products

...like to see the data replicated in other studies, but this is the type of study we must do if we are going to guide people to healthier nutrition that fits with their genetics." To view the published paper please visit http://nutritionjrnl.com/inpress For more information on Interleukin please visit ...

Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery

...a. "We are thrilled to be able to offer these cutting edge procedures to patients at our facility. It allows us to find the treatment option that best fits each individual patient, and we are able to successfully treat the majority of our patients with conservative treatment modalities and identify those ...

CEL-SCI Corporation Releases Letter to Shareholders

...cked to overcome the very complex tumor defense mechanisms and the constant mutation of the tumor antigens cannot be addressed with a 'one key fits all' approach. 3) They act like specific parts of our immune system, when in reality we need a more complete immune approach (the whole army vs. ...

Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases

...lieve the innovative technology platform pioneered by Pacific Pharma may have substantial commercial potential in a number of therapeutic areas and it fits well with our existing core competencies in computational-based approaches to biomarker identification. Pacific Pharma has also generated novel compou...

Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007

...oundations in innovative combinations with new targeted therapies. "This is an exciting time in cancer research as we are moving away from 'one-size fits all' treatment," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "Lilly's commitment to finding ...

PARI and Kamada Announce Positive Intermediate Phase I Results for Inhaled Alpha-1 Antitrypsin

...a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, eFlow helps reduce the burden of taking daily inhaled treatments. For additional information...

Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma

...yeloma toward becoming a chronic disease with long term survival achieved by using drugs in combination and in sequence. The VELCADE/DOXIL combination fits perfectly into this paradigm and offers an important and powerful new opportunity to extend and improve patients' lives." DOXIL is a specially (lipo...

Genetics Journal Thimerosal/Autism Study the 'Best Science Drug Company Money Can Buy'

... have been exposed to RhIg in utero than their non-ASD siblings," according to the SafeMinds analysis. NAA's Fournier points out that the RhIg study fits a recurring pattern for thimerosal research with drug company/researcher ties. Manipulation of data to reach a desired conclusion was seen in CDC stud...

Genzyme Announces Results of Clinical Trial of Hylastan

...ts of viscosupplementation to help manage OA knee pain. We will continue to analyze the findings from the hylastan study to determine how this product fits into our longer-range strategy, as we continue to invest in bringing innovation to this field." About Genzyme One of the world's leading biotechno...
Other Tags
(Date:4/17/2014)... stem cell therapies to cure a variety of diseases ... based on cell surface markers. Researchers from the Finnish ... highly expressed in a type of stem cells derived ... an article in BioResearch Open Access , a ... article is available free on the BioResearch ...
(Date:4/17/2014)... developed at Sandia National Laboratories and recently licensed to ... cheaper. , Bacillus anthracis , the bacteria ... over the world and can cause serious, and often ... can survive in harsh conditions for decades. In humans, ... skin contact, inhalation of spores or eating contaminated meat. ...
(Date:4/17/2014)... produce hydrogen sulfide in order to properly multiply and ... the Center for Craniofacial Molecular Biology at the Herman ... Shi, principal investigator on the project, said the presence ... flow of calcium ions. The essential ions activate a ... the creation of new bone tissue, and keeps the ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
(Date:4/17/2014)... vaccine brands for children may not be the most ... factors when choosing vaccines, driving the market toward what ... new study by University of Illinois researchers. , "The ... numerous factors," says Sheldon H. Jacobson, a co-author of ... of mathematics at the U. of I. "In an ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
Other Contents